This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Minerva Neurosciences Inc. (NASDAQ:NERV). The two are both Biotechnology companies that compete with one another.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vertex Pharmaceuticals Incorporated||211||1.55||256.83M||2.25||99.44|
|Minerva Neurosciences Inc.||6||0.00||33.60M||-1.42||0.00|
Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Vertex Pharmaceuticals Incorporated and Minerva Neurosciences Inc.
Table 2 shows the return on assets, net margins and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Vertex Pharmaceuticals Incorporated||121,858,986.52%||44%||31.4%|
|Minerva Neurosciences Inc.||594,690,265.49%||-76.4%||-44.4%|
Volatility and Risk
Vertex Pharmaceuticals Incorporated’s volatility measures that it’s 48.00% more volatile than Standard and Poor’s 500 due to its 1.48 beta. Competitively, Minerva Neurosciences Inc.’s beta is 1.62 which is 62.00% more volatile than Standard and Poor’s 500.
Vertex Pharmaceuticals Incorporated’s Current Ratio is 3.4 while its Quick Ratio is 3.3. On the competitive side is, Minerva Neurosciences Inc. which has a 6.2 Current Ratio and a 6.2 Quick Ratio. Minerva Neurosciences Inc. is better positioned to pay off short and long-term obligations compared to Vertex Pharmaceuticals Incorporated.
In next table is delivered Vertex Pharmaceuticals Incorporated and Minerva Neurosciences Inc.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Vertex Pharmaceuticals Incorporated||0||1||15||2.94|
|Minerva Neurosciences Inc.||0||0||3||3.00|
Vertex Pharmaceuticals Incorporated has a consensus target price of $229.56, and a 4.83% upside potential. Competitively the average target price of Minerva Neurosciences Inc. is $19, which is potential 155.03% upside. The information presented earlier suggests that Minerva Neurosciences Inc. looks more robust than Vertex Pharmaceuticals Incorporated as far as analyst belief.
Institutional and Insider Ownership
The shares of both Vertex Pharmaceuticals Incorporated and Minerva Neurosciences Inc. are owned by institutional investors at 98.3% and 79.3% respectively. Insiders held 0.1% of Vertex Pharmaceuticals Incorporated shares. Insiders Comparatively, held 0.7% of Minerva Neurosciences Inc. shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Vertex Pharmaceuticals Incorporated||0.68%||13.92%||27.71%||29.17%||24.3%||34.72%|
|Minerva Neurosciences Inc.||0%||21.12%||-15.54%||25.5%||-20.99%||-7.27%|
For the past year Vertex Pharmaceuticals Incorporated had bullish trend while Minerva Neurosciences Inc. had bearish trend.
Vertex Pharmaceuticals Incorporated beats Minerva Neurosciences Inc. on 8 of the 13 factors.
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The companyÂ’s lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The companyÂ’ preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of ParkinsonÂ’s disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.